A bill to require the Secretary of Health and Human Services to establish a demonstration project to increase access to biosimilar biological products under the Medicare program.

Bill 118 s 3934, also known as the "Increasing Access to Biosimilar Biological Products Act," is a proposed piece of legislation that aims to improve access to biosimilar biological products for Medicare beneficiaries. The bill calls for the Secretary of Health and Human Services to establish a demonstration project that would test ways to increase access to these products within the Medicare program.

Biosimilar biological products are a type of medication that are highly similar to existing biological products, but are typically more affordable. By increasing access to these products, the bill aims to lower healthcare costs for Medicare beneficiaries and improve overall healthcare outcomes.

The demonstration project outlined in the bill would test different strategies for increasing access to biosimilar biological products, such as streamlining the approval process for these medications and providing education and outreach to healthcare providers and patients about the benefits of using biosimilars. Overall, the goal of Bill 118 s 3934 is to explore ways to make biosimilar biological products more readily available to Medicare beneficiaries, ultimately leading to cost savings and improved healthcare outcomes for this population.